Payment overview · 2025
General Payments
$178.88
9 reported records · 7 companies
Healthcare provider profile · identity verified
Charles D Baughman, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GROVE CITY, OH · NPI 1669411252
Verified facts
What the public records show
CMS Open Payments records show Charles D Baughman, M.D. received $178.88 in general payments during 2025 across 9 reported records.
ABBVIE INC. accounted for 27.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.99 | 27.4% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $31.15 | 17.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.10 | 13.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.55 | 13.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.76 | 11.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.72 | 8.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.61 | 8.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $178.88 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.18 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $31.15 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.55 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 157 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
66 | 17 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
157 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 998 | 278 |
| Amlodipine Besylate | Amlodipine Besylate | 538 | 147 |
| Lisinopril | Lisinopril | 504 | 147 |
| Levothyroxine Sodium | Levothyroxine Sodium | 500 | 131 |
| Gabapentin | Gabapentin | 376 | 98 |
| Metformin Hcl | Metformin Hcl | 355 | 106 |
| Omeprazole | Omeprazole | 350 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 329 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 321 | 101 |
| Meloxicam | Meloxicam | 316 | 92 |
| Losartan Potassium | Losartan Potassium | 314 | 89 |
| Simvastatin | Simvastatin | 307 | 81 |
| Citalopram Hbr | Citalopram Hydrobromide | 281 | 79 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 272 | 69 |
| Prednisone | Prednisone | 264 | 192 |
| Tamsulosin Hcl | Tamsulosin Hcl | 243 | 62 |
| Glimepiride | Glimepiride | 233 | 74 |
| Potassium Chloride | Potassium Chloride | 220 | 56 |
| Pravastatin Sodium | Pravastatin Sodium | 201 | 57 |
| Furosemide | Furosemide | 200 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 196 | 53 |
| Trazodone Hcl | Trazodone Hcl | 175 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 172 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 158 | 37 |
| Eliquis | Apixaban | 157 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 156 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 147 | 37 |
| Carvedilol | Carvedilol | 143 | 41 |
| Mirtazapine | Mirtazapine | 135 | 34 |
| Pioglitazone Hcl | Pioglitazone Hcl | 127 | 36 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 126 | 34 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 124 | 31 |
| Sertraline Hcl | Sertraline Hcl | 116 | 33 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 113 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 43 |
| Allopurinol | Allopurinol | 109 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 109 | 30 |
| Bupropion Xl | Bupropion Hcl | 107 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 105 | 27 |
| Valsartan | Valsartan | 105 | 31 |
| Januvia | Sitagliptin Phosphate | 98 | 21 |
| Atenolol | Atenolol | 96 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 96 | 20 |
| Spironolactone | Spironolactone | 95 | 30 |
| Chlorthalidone | Chlorthalidone | 91 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 29 |
| Ezetimibe | Ezetimibe | 79 | 22 |
| Metformin Hcl Er | Metformin Hcl | 79 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 77 | 25 |
| Xarelto | Rivaroxaban | 71 | suppressed |
| Synthroid | Levothyroxine Sodium | 66 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 62 | 40 |
| Famotidine | Famotidine | 61 | 19 |
| Ozempic | Semaglutide | 61 | 13 |
| Tramadol Hcl | Tramadol Hcl | 60 | 24 |
| Buspirone Hcl | Buspirone Hcl | 59 | 19 |
| Klor-Con M10 | Potassium Chloride | 58 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | 12 |
| Montelukast Sodium | Montelukast Sodium | 57 | 20 |
| Celecoxib | Celecoxib | 56 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 35 |
| Colestipol Hcl | Colestipol Hcl | 53 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 22 |
| Alprazolam | Alprazolam | 52 | 14 |
| Alendronate Sodium | Alendronate Sodium | 50 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 50 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 37 |
| Levetiracetam | Levetiracetam | 43 | suppressed |
| Jardiance | Empagliflozin | 40 | 11 |
| Aripiprazole | Aripiprazole | 39 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Finasteride | Finasteride | 35 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Klor-Con M20 | Potassium Chloride | 30 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 28 | suppressed |
| Nystatin | Nystatin | 27 | 12 |
| Fluconazole | Fluconazole | 26 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 11 |
| Baclofen | Baclofen | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 16 |
| Diazepam | Diazepam | 22 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 17 |
| Amoxicillin | Amoxicillin | 20 | 14 |
| Cephalexin | Cephalexin | 20 | 18 |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Acyclovir | Acyclovir | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Azithromycin | Azithromycin | 16 | 15 |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 12 |
| Olanzapine | Olanzapine | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $178.88 · 9 records | ABBVIE INC. | AIRSUPRA, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, NURTEC ODT, Ozempic, QULIPTA, UBRELVY, VRAYLAR, Veozah | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error